Pfizer CFO Dave Denton to Step Down in August, Cecile Guegan Named Interim

Pfizer CFO Dave Denton is departing on August 15, 2026 to pursue an opportunity in consumer goods. Cecile Guegan, a 20-year Pfizer veteran currently serving as SVP Finance for the Global Biopharmaceutical Business, will serve as interim CFO starting August 16 while the company runs an internal and external search for a permanent replacement.

Pfizer (PFE) announced on June 18, 2026 that Chief Financial Officer Dave Denton will step down effective August 15, departing to pursue a professional opportunity in the consumer goods industry outside of pharmaceuticals. Cecile Guegan, Senior Vice President of Finance for Pfizer's Global Biopharmaceutical Business, has been named interim CFO and will assume the role on August 16. The two executives will work in parallel through mid-August to ensure a smooth handover. Pfizer has launched a comprehensive internal and external search for a permanent replacement.

Denton joined Pfizer in 2022, bringing experience from CFO stints at CVS Health and Lowe's Companies. During his four-year tenure he helped steer the company through a demanding stretch of capital allocation, including the roughly $43 billion acquisition of oncology specialist Seagen, the Biohaven migraine drug deal, and the Metsera obesity partnership. CEO Albert Bourla publicly credited Denton with guiding the company's financial strategy through that period. Guegan, 55, is a 20-year Pfizer veteran who has held senior finance roles across R&D, regional markets, and the business office. Since 2022 she has led finance for the Global Biopharmaceutical Business, and she was a key figure in integrating Seagen following the 2024 close of that acquisition.

Pfizer's stock dipped modestly on the news, reflecting what analysts read as an orderly, planned transition rather than an emergency departure. The consumer goods destination reduces concerns about Denton moving to a direct pharmaceutical competitor. Investors will be focused on two questions in coming months: how quickly Pfizer names a permanent CFO, and whether the new finance chief maintains or adjusts the capital-allocation priorities, including the company's ongoing cost-restructuring program and pipeline investment pace. Guegan's deep institutional knowledge of the Seagen integration makes her a credible bridge, limiting near-term execution risk.